All stock lists
Avalo Therapeutics, Inc. (NASDAQ:AVTX)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
6.80-0.13 (-1.88%)
Insider Score
––Not scored
AVTX Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
AVTX Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 0.00 | 0.00 | 59.00 K | 0.00 | 0.00 | 0.00 |
| Revenue Growth (YoY) | — | — | -69.27 % | -100.00 % | — | — |
| Cost of Revenue | 0.00 | 17.00 K | 0.00 | 9.99 M | 10.66 M | 5.91 M |
| Gross Profit | 0.00 | -17.00 K | 59.00 K | -9.99 M | -10.66 M | -5.91 M |
| SG&A Expense | 8.10 M | 6.84 M | 6.53 M | 5.58 M | 5.24 M | 5.55 M |
| R&D Expense | 23.42 M | 14.05 M | 13.27 M | 13.62 M | 14.07 M | 9.12 M |
| Operating Expenses | 31.52 M | 20.88 M | 19.80 M | 9.21 M | 8.66 M | 8.76 M |
| Operating Income | -31.52 M | -20.90 M | -19.74 M | -19.20 M | -19.32 M | -14.67 M |
| Pretax Income | -36.34 M | -19.62 M | -13.59 M | -30.61 M | -20.75 M | -13.14 M |
| Tax Provision | 18.00 K | 12.00 K | 130.00 K | 11.00 K | 16.00 K | 8.00 K |
| Net Income | -36.36 M | -19.63 M | -13.72 M | -30.63 M | -20.77 M | -13.15 M |
| EPS (Basic) | -0.83 | -0.98 | -0.74 | -2.19 | -1.92 | -1.25 |
| EPS (Diluted) | -0.83 | -0.98 | -0.74 | -2.19 | -1.92 | -1.25 |
| Shares Outstanding | 43.60 M | 20.11 M | 18.51 M | 14.00 M | 10.83 M | 10.51 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.